RxDoctor Payments DataLook up a doctor →

Delliah Stampp, MD

Family Medicine · Las Cruces, NMNPI 1538342860

Payments from drug & device makers

$20,563in general payments, 2019–2025

Across 698 payments — averaging $29.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$6K
  • Novo Nordisk$3K
  • AstraZeneca$2K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$1K
  • Amgen$1K
  • plus $6K from 37 others

What the payments were for

  • Consulting fees$4,92824%
  • Travel & lodging$1,1936%
  • Food & beverage$14,43570%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,563 in reported general payments places this provider in the 95th percentile of 717 family medicine providers in New Mexico.

See all family medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$102,667
Medicare patients
292
Services billed
1,305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide105$144,542
JardianceEmpagliflozin85$102,241
RybelsusSemaglutide38$90,230
EliquisApixaban31$48,800
ProliaDenosumab27$47,108
MounjaroTirzepatide29$45,985
TrulicityDulaglutide19$29,344
JanuviaSitagliptin Phosphate11$16,020
Repatha SureclickEvolocumab14$12,720
Tresiba Flextouch U-200Insulin Degludec14$11,793
Levothyroxine Sodium367$4,476
Atorvastatin Calcium359$4,124
Omeprazole164$2,840
Losartan Potassium301$2,815
Gabapentin141$2,681

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$3,366$234,772143 claims
Boehringer IngelheimJardiance$1,196$102,24185 claims
Lilly USA, LLCMounjaro, Trulicity$1,213$75,33048 claims
PfizerEliquis$493$48,80031 claims
AmgenProlia$1,065$47,10827 claims
MerckJanuvia$553$16,02011 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$4,476367 claims
AbbVieSynthroid$780$1,77241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 717 family medicine providers in New Mexico.

Other family medicine in Las Cruces

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →